Skip to main content

Advertisement

Table 2 Definitions used in describing the treatment given to the cases in a national cohort of patients with extra-pulmonary tuberculosis

From: Treatment outcome of extra-pulmonary tuberculosis in Finland: a cohort study

Treatment group Drugs used in intensive phase Duration of intensive phase [days] Drugs used in continuation phase Total duration of treatment [months]
Standard treatment A isoniazid + rifampicin + pyrazinamide At least 54 isoniazid + rifampicin At least 5 1/2
Standard treatment B isoniazid + rifampicin + ethambutol or streptomycin At least 54 isoniazid + rifampicin At least 8
Standard treatment with short intensive phase C isoniazid + rifampicin + pyrazinamide or ethambutol or streptomycin Less than 54 isoniazid + rifampicin At least 5 1/2 for A At least 8 for B
Standard treatment D >4 tuberculosis drugs, including the drugs in Standard treatment A or B At least 54 isoniazid + rifampicin + any other anti-tuberculosis drug(s) At least 5 1/2 for A At least 8 for B
Other combination of tuberculosis drugs Non-standard combinations of tuberculosis drugs, excluding the combinations above NA2 Any combination of antituberculosis drugs NA
Ineffective treatment One antituberculosis drug used alone or in combination with a drug with limited antituberculosis activity 1 NA NA NA
  1. 1E.g. fluoroquinolones
  2. 2NA = not applicable